

2 April 2024

Mernova Continues Strong Progress

Highlights:

- **Mernova has successfully received approvals to launch a variety of new SKUs and strains across several provincial markets**
- **Mernova to enter new product category – edible products and has unlocked a new medical channel in its home province**
- **New strains in development to further complement the existing product portfolio**
- **\$1.75m of unaudited revenue delivered in Q1 2024 (up 13% on the PcP: Q1 2024), with Q2 order book already sitting at \$373,000**

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that its wholly owned Canadian subsidiary, Mernova, continues to make strong operational progress. In recent weeks, Mernova has worked diligently to list new SKUs across a variety of key markets. These SKUs include:

- Nova Scotia Liquor Commission
 - Halifax Sage 1g dried flower, launching April 2024
 - 20x0.5g pre-rolls, launching April 2024
 - Ritual Double Double Indica Mixer Pack (two Black Mamba pre-rolls and two Sugar Bomb Punch pre-rolls), launching July 2024
 - Ritual Double Double Sativa Mixer Pack (two French Cookies pre-rolls and two Halifax Sage pre-rolls), launching July 2024
- Ontario Cannabis Store
 - Currently in round two submission approval for the following new SKUs (both launching summer 2024):
 - Sugar Bomb Punch 3.5g dried flower
 - Black Mamba 12x0.5g pre-rolls
- Prince Edward Island, first PO expected for general listing imminently, for following SKUs
 - 3x0.5g pre-rolls for Halifax Sage, French Cookies and Black Mamba
 - 1g vapes for both Black Mamba and Sugar Bomb Punch
 - 1g Black Mamba Bubble Hash Infused Blunt
 - 2x0.5g French Cookies Bubble Hash Infused pre rolls
- Yukon Liquor Commission, launching April 2024
 - Sacred sage 3.5g and 7.0g dried flower
 - Sacred Sage 3x0.5g pre rolls

The Company is very pleased with these results which indicate the demand for Mernova's growing suite of products and strains. Mernova is highly focused on analysing market trends in each of its existing markets and tailoring new products to capture demand. As part of this initiative, Mernova plans to launch its first edible product, and will provide further updates on this in due course. Mernova is also developing two new

strains for markets later in the year; Month Blanc and Dark Star. Finally, the group is also working on developing new flavoured vaporisers with a scheduled launch of Q3 2024.

In an effort to further increase sales, Mernova has signed an agreement with Optimus Cannabis Inc., a local Nova Scotia based pharmacy. Currently, Optimus is ordering a variety of dried flower and pre-roll products. Mernova expects further POs from Optimus imminently, and expects future POs to also include vaporiser products. During Q1 2024, Mernova generated unaudited revenues of \$1.75m, up 13% on the PcP. Mernova has also generated POs for delivery in Q2 2024 of \$373,000, indicating a strong start to the quarter.

Management commentary:

CEO and Managing Director, Mr William Lay said: *“We continue to be highly impressed with the performance of Mernova. A step change in the size of quarterly revenues occurred during FY23 and demand continues to be strong.*

In order to continue its momentum, Mernova’s management has continued to innovate new products and strains and pursue their listing in a variety of markets. We look forward to providing further updates on Mernova in due course.”

Other Updates:

Pursuant to the terms and conditions of a previous maturity extension agreement provided by the Briant Nominees (refer to press release dated 1 Nov 22) the Company has granted the Briant Nominees a general security interest over the Company. The general security ranks behind existing general security held by SBC Global. Separately, the Briant Nominees have issued a 21 day standstill to the Company in order to provide time to negotiate and execute a further extension.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.